Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974321 | 0.89 | CNR1 (0.54) | CNR1CNR2BRS3KCNN4PLCG1 | |
| SCHEMBL5877921 | 0.83 | MAPT (0.50) | CNR1CNR2BRS3KCNN4MAPT | |
| SCHEMBL4678694 | 0.82 | GABRG2 (0.38) | CNR1CNR2TRPV1MAPTAPP | |
| SCHEMBL1107149 | 0.82 | CNR2 (0.57) | CNR1CNR2BRS3KCNN4PLCG1 | |
| SCHEMBL3573740 | 0.82 | CNR1 (0.53) | CNR1CNR2BRS3KCNN4MAPT | |
| SCHEMBL2129349 | 0.81 | TRPV1 (0.44) | CNR1CNR2KCNN4TRPV1MAPT | |
| SCHEMBL23583000 | 0.80 | MAPT (0.59) | CNR1CNR2BRS3KCNN4PLCG1 | |
| SCHEMBL4673000 | 0.80 | CNR1 (0.47) | CNR1CNR2BRS3KCNN4PLCG1 | |
| SCHEMBL8187459 | 0.80 | MAPT (0.56) | CNR1CNR2TRPV1MAPTALDH1A1 | |
| SCHEMBL363770 | 0.80 | CNR1 (0.51) | CNR1CNR2BRS3KCNN4PLCG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427405-B | Tricyclic compounds, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| EP-4177248-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Hefei Institute of Pharmaceutical Industry Co., Ltd. (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HEFEI AMVITE PHARMACEUTICAL CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| CN-115427405-A | Tricyclic compound, preparation method and medical application thereof | 合肥医工医药股份有限公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2022001331-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 合肥医工医药股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| WO-2022001331-A1 | A CLASS OF TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 合肥医工医药股份有限公司 | 2022-01-06 | — | — | WO | disclosed |
| CN-107001213-A | Preparation method and purification method of organic fluorinated aliphatic compound | 财团法人峨山社会福祉财团 | 2017-08-01 | — | — | CN | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1699775-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | Allergan, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140276-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHOD AND MEDICAL USE THEREOF | HNMT, CHRM1, HRH4 | CNR1 40/4885CNR2 42/4885BRS3 805/4885 |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CNR1 492/4885CNR2 675/4885BRS3 2186/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | CNR1 473/4885CNR2 590/4885BRS3 1715/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CNR1 492/4885CNR2 675/4885BRS3 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.